Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* voluntarily~* age \> 18 years old~Exclusion Criteria:~* current use of medication (e.g. analgetics, antiepileptics, antidepressants, etc.)~* prevailing organic disease (e.g. diabetes, vascular or neurologic illness, etc.)~* previous physical trauma of the forearm (e.g. burning, surgery)~* primary organ failure~* pregnancy and lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo first (Type: EXPERIMENTAL): Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
- Flupirtine first (Type: EXPERIMENTAL): Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).